NASDAQ$CTKB
Cytek Biosciences Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Cytek Biosciences' first quarter revenue increased by 44% year-over-year, driven by continued demand across its diversified portfolio and expanded installed base.
Cytek Biosciences reported a strong start to 2022, with first-quarter revenue reaching $35.1 million, a 44% increase compared to the previous year. The company also expanded its installed base to 1,226 instruments and saw growth across its product and service offerings.
- Total revenue for Q1 2022 was $35.1 million, a 44% increase year-over-year.
- The installed base expanded to 1,226 instruments, with 116 instrument placements in Q1.
- Service revenue more than doubled compared to the prior year.
- The company expects full year 2022 revenue to be closer to the high end of the range of $160 million to $168 million.
Headline financials
Revenue & EPS history
Cytek Biosciences · Revenue · Quarterly
$35.1M
Revenue by segment
Cytek Biosciences · $35.1M total across 2 segments · Q1 2022
- Product Revenue$31.5M—89.8%
- Service Revenue$3.58M—10.2%
Forward guidance
Cytek Biosciences expects full year 2022 revenue to be closer to the high end of the range of $160 million to $168 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.9%
Avg return
Earnings day
+0.6%
Avg return
5 days after
-4.5%
Avg return
30 days after
36%
8 / 22 earnings
Positive
+42.3%
Q3 2024
Best reaction
-23.6%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | -18.4% | -17.2% | |
| Q4 2025 | +1.6% | +0.2% | -1.8% | |
| Q3 2025 | +2.6% | +21.5% | +27.6% | |
| Q1 2025 | -22.8% | -28.0% | -9.2% | |
| Q4 2024 | -6.7% | -7.1% | -16.8% | |
| Q3 2024 | +42.3% | +35.6% | +25.8% | |
| Q2 2024 | -12.7% | -10.5% | -6.7% | |
| Q1 2024 | -2.8% | -3.1% | -6.0% | |
| Q4 2023 | -13.0% | -8.2% | -12.9% | |
| Q3 2023 | +14.7% | +12.4% | +75.7% | |
| Q2 2023 | -2.0% | +2.4% | -25.1% | |
| Q1 2023 | -23.6% | -35.4% | -30.9% | |
| Q4 2022 | -10.0% | +0.7% | -15.5% | |
| Q3 2022 | -0.6% | +0.6% | -22.3% | |
| Q2 2022 | +1.0% | +1.9% | -4.0% | |
| Q1 2022 | +1.1% | +23.1% | +25.6% | |
| Q4 2021 | -1.9% | +1.3% | -26.5% | |
| Q3 2020 | +1.8% | -0.2% | -17.9% | |
| Q3 2021 | -0.9% | -4.4% | -19.0% | |
| Q2 2020 | -1.8% | +6.8% | -12.3% | |
| Q4 2020 | -1.8% | +6.8% | -12.3% | |
| Q2 2021 | +16.2% | +14.9% | +2.5% | |
| Q1 2021 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro